Navigation Links
Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
Date:12/12/2013

rogen receptor positive.  In vitro treatment with CB-839 reduced cell viability and induced apoptosis in the majority of triple negative breast cancer cell lines.  CB-839 treatment also resulted in significant anti-tumor activity in two triple-negative breast cancer xenograft models: as a single agent in a patient-derived tumor with a metabolite and expression profile suggestive of high glutamine utilization, and in a second cell line model in which CB-839 demonstrated robust anti-cancer activity both as a single agent and in combination with paclitaxel.

To verify biomarker indicators for CB-839 sensitivity, Calithera researchers studied the Cancer Genome Atlas mRNA expression dataset (n=756) of primary human breast cancers and confirmed a pattern of significantly increased markers of glutaminase in triple-negative breast cancers relative to hormone-receptor driven tumors.  Similar observations were made at the metabolite level in 262 primary breast tumors, suggesting that biomarkers of glutamine utilization and high glutaminase expression may be useful in identifying patients most likely to benefit from CB-839.

Calithera presented these data today during the Tumor Cell and Molecular Biology session in a poster titled:  Antitumor Activity of the Glutaminase Inhibitor, CB-839, in Triple-Negative Breast Cancer (# P2-09-03).

About Calithera Biosciences
Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival.  The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development.  The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics.  Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised
'/>"/>

SOURCE Calithera Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Calithera Biosciences Secures $35 Million in Series D Financing
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
5. Neurocrine Biosciences Reports First Quarter 2012 Results
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
8. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
9. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
10. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
11. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  BioScrip ® , Inc. (NASDAQ: ... President and Chief Executive Officer, will present at the Bank of ... , , , Date: , , , Wednesday, December 3, ... p.m. EST , , , , Location: , , , ... About BioScrip, Inc. BioScrip, Inc. is ...
(Date:11/26/2014)... , Nov. 26, 2014  CARsgen, a leader ... cell immunotherapy to treat a variety of cancers, today ... by BVCF, a China -based healthcare ... immunotherapy company focused on the development of new therapeutics ... with Shanghai Cancer Institute and Shanghai Renji Hospital, the ...
(Date:11/26/2014)... and NEW YORK ... As the leading distributor of market intelligence, ... new research report by IQ4I Research and Consultancy focusing ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast to ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
... 19, 2011 Johnson & Johnson (NYSE: JNJ ... the investment community beginning at 9:00 a.m. (Eastern Time) on ... Brunswick, N.J. ending at approximately 3:00 p.m. Sheri ... Duato and Paul Stoffels, M.D. will host the meeting and ...
... data from multiple clinical trials supporting the safety and ... dual antiplatelet therapy (DAPT) is not advisable were featured ... and treat patients who are not suitable candidates for ... Presenters discussed current treatment alternatives to drug ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 2OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 3OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 4
(Date:11/28/2014)... Agein.com, the Internet’s premier anti-aging web site focusing on anti-aging ... in the industry, is releasing its top diet and personal ... official start of winter is still three weeks away, but ... icy blast. After one of the worst winters in decades ... another brutal winter,” says Dr. Kevin J. McLaughlin, anti-aging and ...
(Date:11/28/2014)... 28, 2014 Junk-A-Car ( http://www.junkacar.com ), ... their service offerings to help drivers, especially those in ... Washington, D.C. metropolitan areas deal with the especially harsh ... large part of the country. , With the high ... hundreds of totaled, crashed and junk cars, ...
(Date:11/28/2014)... 2014 Dr. Andrew Campbell, one of ... the expansion of Quintessa Aesthetic Center into a third ... at W307 N1497 Golf Road in Suite 200 and ... Campbell, the new Delafield location will offer a variety ... including: Botox, filler injectables , micro laser peels, ...
(Date:11/28/2014)... Minneapolis, Minnesota (PRWEB) November 28, 2014 ... one of the few insurance marketing organizations in ... the income and asset protection marketplace. Secura Consultants ... in partnership with Principal Financial Group, a leading ... with multiple ownership interests. With the ownership interest ...
(Date:11/28/2014)... Not only is the Éminence Organic Skin Care team ... other cancer-causing agents, but they are also proud to ... that help in the fight against breast cancer. This ... record-breaking contribution of $30,000 through participation in the CIBC ... Rose Whip Moisturizer and the company’s corporate donation. , ...
Breaking Medicine News(10 mins):Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3
... the United States suggests that the odds of firefighters dying ... fire, //are 10 to 100 times higher than during non-emergency ... ,Stefanos Kales of Harvard Medical School and colleagues say ... in smoke, and lack of physical fitness appeared responsible for ...
... a flight attendant. She started exercising two years back and ... keen that she be agile and strong. ,She ... Her exercise regimen includes balancing on one leg, working with ... fall and break her bones. ,Health experts ...
... used ingredient in the Indian curry powder, could be ... ,ASC-J9, a synthetic chemical compound, derived from ... considerable promise against prostate cancer, acne, and enlarged prostate, ... researchers at the University of Rochester Medical Center ...
... Larry E. Miller and team from Virginia Polytechnic Institute and ... men after one year of coronary artery bypass grafting (CABG). ... than one coronary artery which pass through the heart to ... Twenty six men between the ages of 50 and 79 ...
... only recorded case, turns a mild mannered 70-year-old man into a ... his wife have ‘nightmares’ during the day, of the night to ... after, a different person. He shouts, uses the foulest language, sleepwalks, ... Rogers has broken his nose thrice, ...
... people are turning to the Internet to find information, important ... sheer avalanche of facts// now available online. Key science sites ... results. ,New research funded by the Economic and ... Web to make their information available must now pay attention ...
Cached Medicine News:Health News:New Study Reveals That Firefighters Are Prone To Heart Attack 2Health News:Key Science Web Sites Buried in Information Avalanche 2
...
Stab incision blades color coded for simple and accurate identification...
Atkinson needles have a single bevel with a 22 angle point. Injecting anesthetic agents into the muscle cone. 0.60mm x 38.0mm (23 G x 1 1/2 in)...
Designed to lift corneal cap/flap during corneal lamellar surgery...
Medicine Products: